surmount-1 tirzepatide trial obesity without diabetes 💊 Could a new medication help reduce complications of obesity? The SURMOUNT-MMO investigates tirzepatide, a dual GIP and GLP-1 receptor agonist, in adults with or overweight but diabetes. Researchers SURMOUNT-2: Tirzepatide confers about 15%

The glucagon-like peptide-1 receptor agonist (GLP-1) liraglutide may protect the brains of people with mild Alzheimers disease (AD) and reduce cognitive decline, according to findings presented at the Alzheimers Association International Conference (AAIC) 2024 in Philadelphia and online

Scientists have long noticed similarities between chronic migraines and another brain condition called idiopathic intracranial hypertension without papilledema (IIWHOP)

Monitor hydration status by checking urine colour and frequency

Although safety data could not be pooled due to lack of events, no differences were observed in the risk of severe hypoglycaemia, diabetic ketoacidosis, genitourinary infections and gastrointestinal side effects

[DOI] [PubMed] [Google Scholar] 3.Peptide Therapeutics Market to Reach US$ 49.5 bn by 2027

(The money is likely to fall far short of filling the Medicaid gap, a University of Pennsylvania analysis says.) But theres more to the story, one that depends on adherence to the MAHA agenda in 2026 and beyond